礼来开放其价值超10亿美金AI制药平台！邀中小企业共享“数据金矿”

Core Value - Eli Lilly's Lilly TuneLab is a machine learning platform that leverages over $1 billion worth of drug development models accumulated over years, making it one of the most valuable datasets in the industry [4] - The platform utilizes Federated Learning technology, allowing biotech companies to use Lilly's AI models for drug discovery without sharing their proprietary data [4] Collaboration Model - Biotech companies using the platform are required to contribute their training data, which is aimed at improving the platform and benefiting the entire ecosystem and patients [5] - The initiative is designed to empower smaller biotech firms with the advanced AI capabilities typically available to larger companies [5] Addressing Pain Points - The platform addresses a fundamental barrier faced by small biotech companies, which is the lack of large-scale, high-quality data necessary for training effective models [7] - Lilly TuneLab compresses decades of learning into an immediately usable intelligence resource, thus alleviating the data scarcity issue [7] Future Plans - Eli Lilly plans to enhance TuneLab with additional features, such as in vivo small molecule prediction models, to continuously expand its capabilities [8] - The launch of the AI drug development platform represents a proactive attempt by a pharmaceutical giant to reshape the industry ecosystem and accelerate innovation for data-deficient biotech companies [8]